Applications, hearings, determinations, etc.: Penick Corp.,

[Federal Register: August 6, 2002 (Volume 67, Number 151)]

[Notices]

[Page 50899]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr06au02-92]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 22, 2002, Penick Corporation, 158 Mount Olivet Avenue, Newark, New Jersey 07114, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug

Schedule

Codeine (9050)............................. II Dihydrocodeine (9120)...................... II Oxycodone (9143)........................... II Hydromorphone (9150)....................... II Hydrocodone (9193)........................ II Morphine (9300)............................ II Thebaine (9333)............................ II Oxymorphone (9652)......................... II

The firm plans to manufacture the listed controlled substances for distribution as bulk pharmaceutical products to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filedno later than October 7, 2002.

Dated: July 9, 2002. Laura M. Nagel, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 02-19830Filed8-5-02; 8:45 am]

BILLING CODE 4410-09-M

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT